Efforts at COVID-19 Vaccine Development: Challenges and Successes
Open Access
- 6 December 2020
- Vol. 8 (4), 739
- https://doi.org/10.3390/vaccines8040739
Abstract
The rapid spread of SARS-CoV-2, the new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world.Keywords
This publication has 76 references indexed in Scilit:
- Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus EntryJournal of Virology, 2020
- A plug-and-play approach for malaria vaccinationNature Nanotechnology, 2018
- Post-translational modifications of coronavirus proteins: roles and functionFuture Virology, 2018
- mRNA vaccines — a new era in vaccinologyNature Reviews Drug Discovery, 2018
- Receptor recognition and cross-species infections of SARS coronavirusAntiviral Research, 2013
- The use of Toll-like receptor 7/8 agonists as vaccine adjuvantsExpert Review of Vaccines, 2013
- Correction: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- DNA vaccines: ready for prime time?Nature Reviews Genetics, 2008
- Confronting Potential Influenza A (H5N1) Pandemic with Better VaccinesEmerging Infectious Diseases, 2007